参考文献/References:
[1].Rezkalla SH,Stankowski RV,Hanna J,et al.Management of no-reflow phenomenon in the catheterization laboratory[J].Am Coll Cardiol,2017,10(3): 215-223.
[2].Schram HCF,Hemradj VV,Hermanides RS,et al.Coronary artery ectasia, an independent predictor of no-reflow after primary PCI for ST-elevation myocardial infarction[J].Int J Cardiol,2018,265(3):12-17.
[3].Guo F,Chai W,Liu M,et al.The relationship between MMP-9 and infarct related artery reflow in acute STEMI patients[J].Diabetes Metab,2017,8(2):749.
[4].Bolay?r HA, Güne? H, K?vrak T,et al.The role of SCUBE1 in the pathogenesis of no-reflow phenomenon presenting with ST segment elevation myocardial infarction[J].Anatol J Cardiol, 2017,18(2):122-127.
[5].Durante A,Laricchia A,Benedetti G,et al.Identification of high-risk patients after ST-segment-elevation myocardial infarction: comparison between angiographic and magnetic resonance parameters[J].Circ Cardiovasc Imaging, 2017,10(6):e005841.
[6].Ahmadreza K,Anbukarasi M.Advances in coronary no-reflow phenomenon—a contemporary review[J]. Curr Atheroscler Rep, 2018, 20(9):44.
[7].Fajar JK,Heriansyah T,Rohman MS.The predictors of no reflow phenomenon after percutaneous coronary intervention in patients with ST elevation myocardial infarction: a meta-analysis[J].Indian Heart J,2018,70(Suppl 3): S406-S418.
[8].Scarpone M,Cenko E,Manfrini O.Coronary no-reflow phenomenon in clinical practice[J].Curr Pharm Des,2018,24(25):2927-2933.
[9].Wang K, Zhang J, Zhang N,et al.Combined primary PCI with multiple thrombus burden reduction therapy improved cardiac function in patients with acute anterior myocardial infarction[J].Int Heart J,2019,60(1):27-36.
[10].Scarpone M,Cenko E,Manfrini O.Coronary no-reflow phenomenon in clinical practice[J].Curr Pharm Des,2018,24(25):2927-2933.
[11].Ashoori A,Pourhosseini H,Ghodsi S,et al.CHA2DS2-VASc score as an independent predictor of suboptimal reperfusion and short-term mortality after primary PCI in patients with acute st segment elevation myocardial infarction[J].Medicina (Kaunas),2019,55(2):35.
[12].Su Q,Ye Z,Sun Y,et al.Relationship between circulating miRNA-30e and no-reflow phenomenon in STEMI patients undergoing primary coronary intervention[J].Scand J Clin Lab Invest,2018,78(4):318-324.
[13].Yaylak B,Alt?nta? B,?zcan KS,et al.Relation of hemoglobin level to no-reflow in patients with ST-segment elevation myocardial infarction undergoing primary coronary intervention[J].Postepy Kardiol Interwencyjnej,2018,14(4):383-390.
[14].Pinheiro Machado G,Araujo GN,Carpes CK,et al.Elevated neutrophil-to-lymphocyte ratio can predict procedural adverse events in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention[J].Coron Artery Dis,2019,30(1):20-25.
[15].Ding S,Shi Y,Sun X,et al.Contrast agent dose and slow/no-reflow in percutaneous coronary interventions:a?case-control study of patients with non-ST-segment elevation acute coronary syndromes[J].Herz,2019,44(1):69-75.
[16].García-Méndez RC,Almeida-Gutierrez E,Serrano-Cuevas L,et al.Reduction of no reflow with a loading dose of atorvastatin before primary angioplasty in patients with acute st myocardial infarction[J].Arch Med Res,2018,13(11):6.
[17].Yetgin T, Uitterdijk A, te Lintel Hekkert M, et al. Limitation of infarct size and no-re?ow by intra-coronary adenosine depends critically on dose and duration[J]. JACC Cardiovasc Interv,2015,8(15):1990-1999.
[18].Zhao YJ,Fu XH,Ma XX,et al. Intracoronary ?xed dose nitroprusside via thrombus aspiration catheter for the prevention of the no-re?ow phenomenon following primary percutaneous coronary intervention in acute myocardial infarction[J].Exp Ther Med,2013,6(2):479-484.
[19].Wang L,Cheng Z,Gu Y, et al.Short-term effects of verapamil and diltiazem in the treatment of no re?ow phenomenon:a meta-analysis of randomized controlled trials[J]. Biomed Res Int,2015,2015(4):1-7.
[20].Mehta HH,Morris M,Fischman DL,et al.The spontaneous coronary slow-flow phenomenon: reversal by intracoronary nicardipine[J]. Invasive Cardiol,2019, 31(3):42-45.
[21].Niu X,Zhang J,Bai M,et al. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction:a network meta-analysis[J]. BMC Cardiovasc Disord,2018,18(1):3.
[22].Lago IM,Novaes GC,Badran AV,et al.In-lab upfront use of tirofiban may reduce the occurrence of no-reflow during primary percutaneous coronary intervention. A pilot randomized study[J].Arq Bras Cardiol,2016,107(5):403-410.
[23].Chen WR,Tian F,Chen YD,et al. Effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction[J]. Int J Cardiol,2016, 208(12):109-114.
[24].Qiao J,Pan L,Zhang B,et al. Deferred versus immediate stenting in patients with ST-segment elevation myocardial infarction:a systematic review and meta-analysis[J].Am Heart Assoc,2017,6(3):e004838.
[25].Mewton N,Thibault H,Roubille F,et al. Postconditioning attenuates no-reflow in STEMI patients[J]. Basic Res Cardiol,2013,108(6):383.
[26].Hahn JY,Song YB,Kim EK,et al.Ischemic postconditioning during primary percutaneous coronary intervention:the effects of postconditioning on myocardial reperfusion in patients with ST-segment elevation myocardial infarction(POST) randomized trial[J]. Circulation,2013,128(17):1889-1896.
[27].Herring MJ,Dai W,Hale SL,et al. Rapid induction of hypothermia by the ThermoSuit system profoundly reduces infarct size and anatomic zone of no re?ow following ischemia reperfusion in rabbit and rat hearts[J].Cardiovasc Pharmacol Ther,2015,20(2):193-202.
[28].Zhou H,He XY,Zhuang SW,et al. Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention[J].World J Emerg Med,2014,5(2):96-102.
[29].Backhaus T,Fach A,Schmucker J,et al. Management and predictors of outcome in unselected patients with cardiogenic shock complicating acute ST-segment elevation myocardial infarction:results from the Bremen STEMI Registry[J].Clin Res Cardiol,2018,107(5):371-379.
相似文献/References:
[1]林远龙,刘现亮.无复流现象:从基础到临床[J].心血管病学进展,2016,(1):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
LIN Yuanlong,LIU Xianliang.From Bench to Bed:No-reflow Phenomenon[J].Advances in Cardiovascular Diseases,2016,(5):53.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.014]
[2]赵劲东,综述,董平栓,等.合并多支血管病变的急性ST段抬高型心肌梗死介入术治疗策略的研究进展[J].心血管病学进展,2016,(3):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
ZHAO Jindong,DONG Pingshuan.Research Progress of Interventional Therapy in Patients with ST-elevation
Myocardial Infarction and Multivessel Disease[J].Advances in Cardiovascular Diseases,2016,(5):295.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.021]
[3]余正春,综述,马小静,等.急性心肌梗死并发心源性休克的治疗进展[J].心血管病学进展,2016,(4):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
YU Zhengchun,MA Xiaojing.Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2016,(5):441.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.029]
[4]袁帅,毛玉琳,钱志敏,等.经皮冠脉介入术在高龄老年患者治疗中的研究新进展[J].心血管病学进展,2019,(6):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
YUAN Shuai,MAO Yulin,QIAN Zhimin,et al.New Progress in Study of PCI in treatment of Elderly Patients[J].Advances in Cardiovascular Diseases,2019,(5):864.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.007]
[5]元洋洋 李波.Selvester QRS评分系统研究进展[J].心血管病学进展,2019,(7):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
YUAN YangyangLI Bo.Research Progress of Selvester QRS Scoring System[J].Advances in Cardiovascular Diseases,2019,(5):985.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.005]
[6]翁子骞 于波.血栓抽吸在急性ST段抬高型心肌梗死中的研究进展[J].心血管病学进展,2019,(7):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
WENG ZiqianYU Bo.Thrombus aspiration in acute ST-segment elevation myocardial infarction[J].Advances in Cardiovascular Diseases,2019,(5):1035.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.018]
[7]林莉 韦铁民.急性心肌梗死后心脏破裂[J].心血管病学进展,2019,(7):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
LIN LiWEI Tiemin.Post-infarction Cardiac Rupture[J].Advances in Cardiovascular Diseases,2019,(5):1039.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.019]
[8]杨颜瑜,苏星,谭敏,等.炎症指标与急性心肌梗死研究进展[J].心血管病学进展,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
YANG Yanyu,SU Xing,TAN Min,et al.Relationship Between Inflammation Index and Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(5):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
[9]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[10]朱建中 吴倩芸 刘峰.急性ST段抬高型心肌梗死“导管室误激活”的临床进展[J].心血管病学进展,2019,(5):739.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.019]
ZHU JianzhongWU QianyunLIU Feng.The Development of False-positive Activation of Cardiac Catheterization Laboratory with Acute ST Segment Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(5):739.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.019]